63 results about "Glutarimide" patented technology

The invention discloses heat-resistant polymethyl methacrylate, a preparation method thereof and an optical film. The heat-resistant polymethyl methacrylate comprises a methyl methacrylate repetitive unit, a glutarimide repetitive unit and an N-methyl methacrylamide repetitive unit, and the sum of the number of the glutarimide constitutional unit and the number of the N-methyl methacrylamide constitutional unit is 1-20 mol% of the total number of the constitutional units. The glutarimide structural unit can be obtained by further cyclization reaction of an N-methyl methacrylamide structural unit, and the cyclization rate can be increased to 80-90% by adding a cyclization accelerator such as triethylamine, so that the thermal stability of the resin is improved, and the water absorption rate is reduced. The material can be used for preparing an optical film, has excellent heat resistance and moisture resistance, and is suitable for the field of optical display.

Disclosed in the present invention are a glutarimide compound, and the use thereof. Specifically disclosed are a compound as represented by formula (VII-0) and a pharmaceutically acceptable salt thereof.

This invention provides Degron compounds which bind to cereblon which is a component of the E3 ubiquitin ligase. The Degrons provided herein can be used to modulate the activity of cereblon either alone or as covalently linked to a Tail. Alternatively, the Degron can be linked to a Targeting Ligand which binds to a Target Protein for protein degradation.

The application discloses a bacteriostatic and deodorizing zeolite cat litter and a preparation method thereof, and belongs to the technical field of zeolite cat litter preparation. The bacteriostatic and deodorizing zeolite cat litter is composed of the following components in parts by weight: 55-75 parts of modified zeolite, 3-6 parts of bacteriostatic gel, 2-5 parts of adhesive, and 1-3 parts of filler. The modified zeolite is prepared from sulfamic acid, N,N-dimethylformamide, lignocellulose and zeolite, and the bacteriostatic agent is prepared from four-arm polyethylene glycol, succinic anhydride, triethylamine, N-hydroxyl glutarimide, 1-(3-dimethylaminopropyl)-3-ethyl carbodiimide hydrochloride and polylysine. The zeolite cat litter prepared by the method has excellent water absorption, antibacterial property and deodorizing property.

The invention belongs to the technical field of medicine synthesis processes, and particularly relates to a preparation method of high-yield and high-purity buspirone hydrochloride. According to the method, 8-(2-pyrimidinyl)-8-aza-5-5-azonium spiro [4.5] decane hydrobromide (pyrimidino piperazine quaternary ammonium salt for short) and 3, 3-tetramethylene glutarimide are taken as raw materials, a mixed solvent of methylbenzene and n-amyl alcohol and / or n-hexanol is taken as a solvent, buspirone can be generated in the presence of sodium carbonate without adding a phase transfer catalyst, and buspirone can be obtained through acid adjustment and extraction. After toluene reverse phase impurity removal, a water phase is adjusted to be alkaline, an ethanol solution of hydrogen chloride is added after toluene extraction, and buspirone hydrochloride solid is directly separated out. The preparation process has a very good cleaning effect on impurities, and the obtained buspirone hydrochloride is high in purity, high in process yield, good in atom economy and low in output of three wastes.

This invention belongs to the field of pharmaceutical chemistry technology, and discloses a compound and its uses. Specifically, it relates to a CRBN small molecule ligand compound based on a pyridazine-glutarimide core skeleton (PDG), its composition, and its application. It also relates to a protein degrading agent based on a CRBN small molecule ligand compound based on a pyridazine-glutarimide core skeleton (PDG) and its application. Specifically, the CRBN small molecule ligand compound is shown in (Ⅰ): wherein R... 1 and R 2 Selected from one or more of the following: fused rings attached to a pyridazine core, H, alkyl, OR, F, CN, CF3, NR2, Ph, 4-Py; Y selected from one or more of CH, CD, CF, and N; R 3 Selected from one or more of OR, NR2, CHR2, and C≡CR; R 4 Selected from H or alkyl.

The present disclosure relates to a compound of Formula (I) or a salt, a solvate, an isotopically enriched analog, a tautomer, a polymorph, a stereoisomer thereof, or a mixture of stereoisomers thereof, and their use for treating a tumor. The present disclosure also relates to a compound of Formula (I′) or a pharmaceutically acceptable salt, a solvate, an isotopically enriched analog, a tautomer, a polymorph, a stereoisomer thereof, or a mixture of stereoisomers thereof, and their use for treating a tumor.

Provided are: a resin composition containing 30-85 parts by mass of an acrylic resin (A) and 15-70 parts by mass of an aromatic vinyl resin (B), the acrylic resin (A) contains 60-95% by mass of a (meth) acrylic monomer unit and 5-40% by mass in total of at least one selected from the group consisting of a glutaric anhydride unit, a glutaric imide unit, an N-substituted maleimide unit and a lactone ring unit. The aromatic vinyl resin (B) contains 55-93% by mass of an aromatic vinyl monomer unit and 7-45% by mass of an N-substituted maleimide unit.

The present invention provides degron bodies with carbon-linked E3 ubiquitin ligase targeting moieties (degrons) that can be linked to targeting ligands for proteins selected for degradation in vivo, methods and compositions for their use, and methods for their preparation.

The present invention provides a method for manufacturing acrylic resins, acrylic resin films, and acrylic resin molded articles that exhibit excellent resistance to roll contamination and heat resistance during film formation. [Solution] The method for producing an acrylic resin molded article includes a step of melt-molding an acrylic resin using an extruder, the resin containing methyl methacrylate units and having one or more ring structures selected from the group consisting of glutarimide rings, lactone rings, maleic anhydride rings, glutaric acid anhydride rings, and maleimide rings in its main chain. If the content of methyl methacrylate dimers in the acrylic resin and the content of methyl methacrylate dimers in the acrylic resin molded article are A [ppm by weight] and B [ppm by weight], respectively, then the formula [(AB) / A] × 100 The reduction rate of methyl methacrylate dimers calculated by this method is 50% or more.

This invention provides Degron compounds which bind to cereblon which is a component of the E3 ubiquitin ligase. The Degrons provided herein can be used to modulate the activity of cereblon either alone or as covalently linked to a Tail. Alternatively, the Degron can be linked to a Targeting Ligand which binds to a Target Protein for protein degradation.

The present disclosure provides a compound of Formula (I) or salts, enantiomers, stereoisomers, solvates, or polymorphs thereof and uses thereof. The present disclosure also provides pharmaceutical compositions comprising, as an active ingredient, the compound of Formula (I) or salts, enantiomers, stereoisomers, solvates, or polymorphs thereof and uses thereof. The series of compounds designed and synthesized in the present disclosure can effectively prevent and / or treat diseases or disorders associated with the cereblon protein.

This invention provides Degron compounds which bind to cereblon which is a component of the E3 ubiquitin ligase. The Degrons provided herein can be used to modulate the activity of cereblon either alone or as covalently linked to a Tail. Alternatively, the Degron can be linked to a Targeting Ligand which binds to a Target Protein for protein degradation.

The present disclosure relates to the technical field of molecular glue decomposers, and in particular to a compound of formula I based on a sulfur / oxygen substituted glutarimidylimide isoindolinone skeleton and its applications. The present disclosure further relates to a compound of formula A and its applications. JPEG2026502207000117.jpg44146

The present disclosure relates to the technical field of molecular glue degraders, and particularly to a sulfur / oxygen substituted glutarimide-isoindolinone skeleton-based compound of Formula I, and uses thereof. The present disclosure further pertains to a compound of Formula A and its uses.

The present invention discloses crystals of naphthofuran-substituted glutarimide compounds, a method for producing the same, and uses thereof, and more specifically, the present invention discloses crystals of compound (1) and the production thereof. JPEG2025531599000016.jpg3499

The present disclosure provides a compound of Formula (I) or salts, enantiomers, stereoisomers, solvates, or polymorphs thereof and uses thereof. The present disclosure also provides pharmaceutical compositions comprising, as an active ingredient, the compound of Formula (I) or salts, enantiomers, stereoisomers, solvates, or polymorphs thereof and uses thereof. The series of compounds designed and synthesized in the present disclosure can effectively prevent and / or treat diseases or disorders associated with the cereblon protein.

A resin composition containing 30 to 85 parts by mass of an acrylic resin (A) and 15 to 70 parts by mass of an aromatic vinyl resin (B), wherein the acrylic resin A contains 60 to 95% by mass of (meth)acrylic monomer units and 5 to 40% by mass in total of at least one selected from the group consisting of glutaric anhydride units, glutarimide units, N-substituted maleimide units, and lactone ring units, and the aromatic vinyl resin (B) contains 55 to 93% by mass of aromatic vinyl monomer units and 7 to 45% by mass of N-substituted maleimide units. A plate-shaped molded article and a multilayered article are provided.

The invention relates to the field of organic synthesis, in particular to a preparation method and application of glutarimide compounds, and the preparation method comprises the following steps: in the presence of formic acid, a compound II reacts with formamide to prepare a compound I. According to the preparation method, glutaric acid compounds and formamide are adopted as starting raw materials, and the yield of 80% or above can be obtained under the condition that no additional reaction solvent is used only by adding a catalytic amount of formic acid into a reaction system. # imgabs0 #

The present disclosure relates to a compound of Formula (I) or a salt, a solvate, an isotopically enriched analog, a tautomer, a polymorph, a stereoisomer thereof, or a mixture of stereoisomers thereof, and their use for treating a tumor. The present disclosure also relates to a compound of Formula (I′) or a pharmaceutically acceptable salt, a solvate, an isotopically enriched analog, a tautomer, a polymorph, a stereoisomer thereof, or a mixture of stereoisomers thereof, and their use for treating a tumor.

The application relates to the field of organic synthesis, in particular to a preparation method and application of a glutarimide compound, which comprises the following steps: reacting a compound II and a formamide in the presence of formic acid to prepare a compound I. The preparation method adopts glutaric acid compounds and formamide as starting materials, only needs to add a catalytic amount of formic acid in a reaction system, and can obtain a yield of more than 80% without using any additional reaction solvent.

The present invention relates to an isoindolinone derivative compound having a glutarimide mother nucleus, and the application thereof and, more specifically, to an isoindolinone derivative compound having a glutarimide mother nucleus having a thalidomide analog. The compound of chemical formula 1 according to the present invention specifically binds to the CRBN protein and is involved in functions thereof. Thus, the compound of the present invention may be beneficially used in the prevention or treatment of leprosy, chronic graft versus host disease, inflammatory diseases, or cancer that are caused by actions of the CRBN protein.

The present disclosure provides compounds of formula (I): which induce proteolysis of the proto-oncogene tyrosine protein kinase receptor (RET), which may be either wild-type or mutant RET (useful in the treatment of diseases and disorders mediated by said protein): This relates to the compound represented by TIFF2026506696000135.tif42150.

The present invention provides amine-linked C3-glutarimide degradation determinants and degradation determinants for therapeutic applications as further described herein, methods of use and compositions thereof, and methods of their preparation.

The present invention relates to an isoindolinone derivative compound having a quinoline-substituted glutarimide parent nucleus and an application thereof, and more particularly, to an isoindolinone derivative compound having a thalidomide analogue structure and having a quinoline-substituted glutarimide parent nucleus. The compound of chemical formula 1 according to the present invention specifically binds to CRBN protein and participates in its function. Therefore, the compound of the present invention can be effectively used for preventing or treating leprosy, chronic graft versus host disease, inflammatory disease or cancer caused by the action of CRBN protein.

The present invention relates to a glutarimide compound, the chemical structure of which is shown in the following formula (I): wherein L is selected from D and a glutarimide compound is selected from the present invention, which can simultaneously degrade BDR4 and GSPT1. The compound shows a good killing effect on blood system tumor cells (including multiple myeloma, lymphoma and leukemia), which is better than the clinical candidate drug CC-90009.

This invention provides amine-linked C3-glutarimide Degronimers and Degrons for therapeutic applications as described further herein, and methods of use and compositions thereof as well as methods for their preparation.

To provide a methacrylic polymer which has high heat resistance, a high coefficient of elasticity, a not high coefficient of water absorption, and good heat and warm water stability.SOLUTION: A methacrylic copolymer comprises: 15-83 mass% of methyl methacrylate units; 7-35 mass% of α-methylstyrene units; 0-20 mass% of maleic anhydride units (M); 10-65 mass% of structural units (R) having in the main chain at least one or more ring structures selected from the group consisting of a lactone ring unit, a glutaric anhydride unit, an N-substituted or -unsubstituted glutarimide unit, and an N-substituted or -unsubstituted maleimide unit; and 0-20 mass% of other vinylic monomer units (C) copolymerizable with methyl methacrylate units.SELECTED DRAWING: None

The invention discloses a hydantoinase mutant, immobilized hydantoinase and application of the immobilized hydantoinase in synthesis of a pregabalin intermediate, and belongs to the technical field of biological catalytic synthesis. According to the present invention, the activity of the hydantoinase is modified by using the molecular modification technology, the hydantoinase is immobilized by using the immobilization technology on the basis, and the immobilization conditions (temperature, pH and time) are optimized, such that the optimal scheme for preparing the immobilized hydantoinase is provided, and the pregabalin intermediate is produced by using the 3-isobutyl glutarimide as the substrate through the biological catalysis reaction; the conversion rate after the immobilized enzyme is repeatedly used for 17 times is not lower than 98%, the ee value of the product is not lower than 99%, reaction liquid and the immobilized enzyme can be obtained by direct separation through suction filtration after the reaction is finished, post-treatment steps are simplified, the production cost is reduced, the yield is increased, and the method has high industrial application value.

In one aspect, the disclosure relates to compounds of Formula (I) comprising a cereblon degrader precursor comprising an acyclic glutarimide moiety. In certain embodiments, the acyclic glutarimide moiety7 converts to a glutarimide moiety7 upon exposure to a stimulus. In certain embodiments, the compound of Formula (I) comprises at least one selected from the group consisting of a Proteolysis Targeting Chimera (PROTAC). degrader antibody conjugate (DAC), and / or Immunomodulatory Imide Drug (IMiD). In another aspect, the disclosure relates to methods of use of the compounds described herein for the treatment of a disease or disorder, including but not limited to cancer.